Tupper J T, Bodine P V
J Cell Physiol. 1983 May;115(2):159-66. doi: 10.1002/jcp.1041150209.
Lowering of extracellular Ca2+ levels will reversibly arrest the growth of human fibroblasts (WI38). Simian virus40(SV40)-transformed WI38 cells do not exhibit this Ca2+-dependent arrest. One possibility for this difference in Ca2+ requirement is that extracellular or surface membrane-bound Ca2+ may be required for growth factor receptor-mediated endocytosis and this Ca2+ requirement may differ in normal versus transformed cells. In this study we have evaluated the role of Ca2+ in the binding, internalization, and degradation of epidermal growth factor (EGF) in the WI38 and SV40WI38 cell. The binding of [125I]EGF to the cell surface is not significantly altered by lowering of Ca2+ to 10(5)-M levels in either the normal or transformed cell. At this Ca2+ level, growth of the normal cell is inhibited. The subsequent internalization of EGF is reduced nearly threefold in the normal cell but not in the transformed cell following Ca2+ deprivation. Degradation of the EGF-receptor complex is also sensitive to Ca2+. A twofold reduction in the rate of release of acid-soluble 125I occurs in the normal but not the transformed cell under conditions of lowered medium Ca2+. In contrast, 2-chloro-10-3-aminopropyl phenothiazine (CP), an inhibitor of the Ca2+-dependent regulator protein calmodulin, causes an inhibition of [125I]EGF internalization and degradation in both the normal and transformed WI38 cell, and a marked inhibition of [125I]EGF binding to the cell surface receptor of the transformed cell but not the normal cell.
降低细胞外钙离子(Ca2+)水平会使人类成纤维细胞(WI38)的生长可逆性停滞。猿猴病毒40(SV40)转化的WI38细胞不会出现这种依赖钙离子的停滞现象。钙离子需求存在这种差异的一种可能性是,生长因子受体介导的内吞作用可能需要细胞外或表面膜结合的钙离子,而这种钙离子需求在正常细胞与转化细胞中可能有所不同。在本研究中,我们评估了钙离子在WI38和SV40WI38细胞中表皮生长因子(EGF)的结合、内化和降解过程中的作用。在正常细胞或转化细胞中,将钙离子水平降低至10^(-5)M时,[125I]EGF与细胞表面的结合没有显著改变。在此钙离子水平下,正常细胞的生长受到抑制。钙离子剥夺后,正常细胞中EGF的后续内化减少了近三倍,而转化细胞中则没有。EGF-受体复合物的降解也对钙离子敏感。在培养基钙离子水平降低的条件下,正常细胞中酸溶性125I的释放速率降低了两倍,而转化细胞中则没有。相比之下,钙离子依赖性调节蛋白钙调蛋白的抑制剂2-氯-10-(3-氨丙基)吩噻嗪(CP)会抑制正常和转化的WI38细胞中[125I]EGF的内化和降解,并且显著抑制转化细胞而非正常细胞中[125I]EGF与细胞表面受体的结合。